Biopharmaceutical company Dizal (SSE:688192) announced on Friday that it has submitted a New Drug Application (NDA) to the US FDA for sunvozertinib, targeting locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) post-platinum-based chemotherapy.
Data from the pivotal WU-KONG1 Part B study, featured at the 2024 ASCO Annual Meeting, supports the application, highlighting significant objective response rates and a manageable safety profile.
Sunvozertinib, an oral EGFR inhibitor, previously received accelerated approval in China and Breakthrough Therapy Designations from both the US FDA and China CDE. Demonstrating efficacy across various EGFR exon20ins subtypes and brain metastasis cases, the drug addresses a key unmet need, improving outcomes for patients with poorer prognosis.
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma